Oncology Subscribe

Best Practices for the Medical Oncology Boards

Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

July 7th 2025

Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS

July 3rd 2025

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Roman Fabbricatore

July 10th 2025

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis.

Keerthana Sureshkumar;Richa Dawar

July 10th 2025

Tislelizumab/Chemotherapy Earns EU Approval in Nasopharyngeal Carcinoma

Related Content

Best Practices for the Medical Oncology Boards

Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

July 7th 2025

Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS

July 3rd 2025

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Roman Fabbricatore

July 10th 2025